Robert Bristow, MD, PhD; University of Manchester, U.K.
“Model Development and Assessment to Explain Heterogeneity in Localized BRCA2 Prostate Cancer”
Alan D’Andrea, MD; Dana-Farber Cancer Institute
“Prevention of PARP Inhibitor Resistance in BRCA2-Mutated Prostate Cancers by Inhibiting POLQ”
Rosalind Eeles, PhD; The Institute of Cancer Research, U.K.
“BRCA1 And BRCA2 Mutation Carriers – Prostate Cancer Screening And Treatment Outcomes”
Maria Jasin, PhD; Memorial Sloan Kettering Cancer Center
“BRCA2 Mutant Prostate Cancer and the Impact of DNA Replication Factor Perturbation in Therapy Resistance”
Ephrat Levy-Lahad, MD; Shaare Zedek Medical Center, Israel
“Presymptomatic Awareness of Germline Pathogenic BRCA Variants and Associated Outcomes in Male BRCA carriers with Prostate Cancer”
Daniel W. Lin, MD; University of Washington
“Prostate Cancer Screening for People at Genetic Risk for Aggressive Disease (PATROL)”
Kara Maxwell, MD, PhD; University of Pennsylvania
“The Role of BRCA2 Regulation of Androgen Signaling In Prostate Tumors and the Tumor Microenvironment”
Katherine Nathanson, MD; University of Pennsylvania
“Expanding The Spectrum of BRCA1/2 Pathogenic Variants”
Kenneth Offit, MD, MPH; Memorial Sloan Kettering Cancer Center
“Targeting BRCA1/2 Modifiers of Risk for Prostate Cancer”
Kimberly Rickman MD, PhD; University of California San Francisco
“Defining Prostate Cancer Tumor-Immune Interactions in BRCA2 Deficiency to Identify Therapeutic Vulnerabilities”
Ann & Robert H. Lurie Children’s Hospital of Chicago; Polsky Family Genetic Testing Initiative
This collaboration will expand access to vital genetic testing for patients and families, with an estimated 275 individuals benefiting through the Cancer Predisposition Program in Lurie Children’s Center for Cancer and Blood Disorders.